phosphorylcholine has been researched along with Chagas Disease in 5 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Chagas Disease: Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Trypanosoma cruzi, the Chagas disease etiological agent, is sensitive to APs (edelfosine, miltefosine and ilmofosine) in vitro." | 3.91 | In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects. ( Barrias, E; Calogeropoulou, T; de Souza, W; Reignault, LC, 2019) |
| "Amiodarone is also capable to inhibit the oxidosqualene cyclase, a key enzyme in the synthesis of ergosterol." | 2.47 | Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review. ( Benaim, B; Garcia, CR, 2011) |
| " This alkylphospholipid was also extremely toxic against intracellular amastigotes of both strains." | 1.31 | Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi. ( Bozza, MT; Freire-De-Lima, CG; Gibaldi, D; Heise, N; Mendonça-Previato, L; Previato, JO; Saraiva, VB, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gulin, JEN | 1 |
| Bisio, MMC | 1 |
| Rocco, D | 1 |
| Altcheh, J | 1 |
| Solana, ME | 1 |
| García-Bournissen, F | 1 |
| Barrias, E | 1 |
| Reignault, LC | 1 |
| Calogeropoulou, T | 1 |
| de Souza, W | 1 |
| Benaim, B | 1 |
| Garcia, CR | 1 |
| Saraiva, VB | 1 |
| Gibaldi, D | 1 |
| Previato, JO | 1 |
| Mendonça-Previato, L | 1 |
| Bozza, MT | 1 |
| Freire-De-Lima, CG | 1 |
| Heise, N | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Yardley, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
1 review available for phosphorylcholine and Chagas Disease
| Article | Year |
|---|---|
Targeting calcium homeostasis as the therapy of Chagas' disease and leishmaniasis - a review.
Topics: Amiodarone; Antiprotozoal Agents; Calcium; Chagas Disease; Homeostasis; Humans; Leishmania; Leishman | 2011 |
4 other studies available for phosphorylcholine and Chagas Disease
| Article | Year |
|---|---|
Miltefosine and Benznidazole Combination Improve Anti-
Topics: Animals; Chagas Disease; Mice; Nitroimidazoles; Parasitemia; Phosphorylcholine; Trypanocidal Agents; | 2022 |
In vitro activities of adamantylidene-substituted alkylphosphocholine TCAN26 against Trypanosoma cruzi: Antiproliferative and ultrastructural effects.
Topics: Adamantane; Animals; Antiprotozoal Agents; Autophagy; Cell Membrane; Chagas Disease; Dose-Response R | 2019 |
Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.
Topics: Animals; Antiprotozoal Agents; Chagas Disease; Drug Resistance; Exudates and Transudates; Inflammati | 2002 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |